Health

U.S. Drug Distribution Industry Expands as COVID-19 Disruption Fades and Biosimilars Boom

Leave a comment


The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

The Inflation Reduction Act of 2022 will trigger multiple changes in pharmacy and provider markets that will negatively impact wholesalers, although wholesalers may indirectly benefit from certain aspects of the legislation.


PHILADELPHIA (PRWEB)

Today Drug Channels Institute (DCI) released its exclusive analysis of U.S. prescription drug distribution channels. DCI’s new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors delves into the business operations and industry environment of the Big Three public drug wholesalers—AmerisourceBergen, Cardinal Health, and McKesson.

“U.S. drug distribution revenues at the largest wholesalers have accelerated, as pharmacy and provider markets have recovered from the disruptions of the COVID-19 pandemic,” says Drug Channels Institute CEO Adam J. Fein, Ph.D., the study’s author and a widely regarded expert on pharmaceutical economics and the drug distribution system. “Wholesalers now generate significant profits from provider-administered biosimilar drugs. We project that overall U.S. drug distribution revenues at the Big Three wholesalers will reach $616 billion in 2022.”

Now in its 13th edition, The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors offers 150 proprietary charts, exhibits, and data tables. It remains the most comprehensive resource for analyzing the pharmaceutical distribution industry’s economics, market structure, growth rates, forces of change, and interactions within the U.S. healthcare system. The new report also provides an updated analysis of each of the Big Three public companies’ business segments and underlying profitability, based upon DCI’s proprietary economic models.

The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors analyzes the crucial healthcare trends affecting pharmaceutical wholesalers, including: the outlook for brand-name drug prices; the evolution of the pharmacy industry; changes to buy-and-bill channels; vertical integration by hospitals; cell and gene therapies; importation; and much more.

Fein adds, “The Inflation Reduction Act of 2022 will trigger multiple changes in pharmacy and provider markets that will negatively impact wholesalers, although wholesalers may indirectly benefit from certain aspects of the legislation.”

To purchase and immediately download the new report, visit https://drugch.nl/wholesale. To read a free report overview, visit https://drugch.nl/overview-2022-23

About Drug Channels Institute

Drug Channels Institute is a leading source of industry research about pharmaceutical economics and the drug distribution system. To learn more about its products, visit http://www.drugchannelsinstitute.com. Access Dr. Fein’s popular Drug Channels blog at http://www.drugchannels.net.

Media Contact:

Tamra Feldman

Drug Channels Institute

215-523-5700

Email: admin@drugchannels.net

Share article on social media or email:

Leave a Reply